23andMe launches new genetic report on osteoporosis

23andMe (ME) Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report informs customers if they are at a higher likelihood of developing osteoporosis based on a statistical model developed by 23andMe through its proprietary research database, along with actionable lifestyle factors that can reduce their risk. “Predominantly diagnosed in women, there are around 2 million new osteoporosis-related fractures in the U.S. each year, which is more than the number of new cases of heart attacks, breast cancer, and prostate cancer combined,” said Dr. Noura Abul-Husn, VP of Genomic Health. “We’re proud to continue our commitment to developing genetic reports that impact women’s health, adding osteoporosis to our existing slate of offerings that include breast cancer, gestational diabetes, polycystic ovary syndrome, uterine fibroids, among others.” 23andMe’s Osteoporosis PRS report is based on a statistical model developed by 23andMe through its proprietary research database. The report takes into account an individual’s genetic results at many genetic markers, along with their genetic ancestry and birth sex to estimate the likelihood of developing osteoporosis. According to published data, it’s estimated that genetics explains ~60-80% of the variability in bone density.